Novasep Commissions Plant Extension for Highly Potent APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novasep Commissions Plant Extension for Highly Potent APIs

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

Novasep expanded its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France; the plant extension has been fully qualified and is now being used to scale up validation of a commercial antibody-drug conjugate (ADC) payload. 
 


HPAPI, the majority of which are used in anti-cancer therapies, must be produced under strict regulatory conditions to protect any API substance from cross contamination and protect operators from the highly active properties that are intrinsic to these products. Ensuring supply chain continuity is also important to meet the rising demand in the pharmaceutical industry for ADCs.
 “There is a high demand from the pharmaceutical industry for CMOs to manufacture potent molecules for use in drugs that improve efficacy and reduce side effects," said Thierry Van Nieuwenhove, president of the Synthesis Business unit at Novasep.


The Le Mans production facility combines chemical and purification capabilities to manufacture potent and extremely potent ADC payloads at commercial scale with an occupational exposure limit lower than 30 ng/m3 at multi-kg scale per batch.
 
The production suite can also perform cryogenic chemistry at -60 °C in Hastelloy reactors.

Source: Novasep

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here